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In Brief
Garman et al. have characterized
melanoma PDXs and cell lines described
in Krepler et al. (see the related paper in
this issue of Cell Reports), identifying
major and minor subtypes, some of which
were previously not well defined, targeted
and immunotherapy resistance, and
tumor heterogeneity, creating a set of
reagents for future drug discovery and
biological studies.
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Melanoma cell lines and PDXs more likely to be BRAF/NRAS
mutant than patient tumors
Mutations in melanoma PDXs are concordant with tumors
from which they are derived
Contrasting MAPK pathway mutation patterns: one high
activity, several low activity
Recurrent disease displays intra- and inter-tumor mutational
heterogeneity
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SUMMARY

Tumor-sequencing studies have revealed the widespread genetic diversity of melanoma. Sequencing
of 108 genes previously implicated in melanomagenesis was performed on 462 patient-derived xenografts (PDXs), cell lines, and tumors to identify
mutational and copy number aberrations. Samples
came from 371 unique individuals: 263 were naive
to treatment, and 108 were previously treated with
targeted therapy (34), immunotherapy (54), or both
(20). Models of all previously reported major melanoma subtypes (BRAF, NRAS, NF1, KIT, and WT/
WT/WT) were identified. Multiple minor melanoma
subtypes were also recapitulated, including melanomas with multiple activating mutations in the
MAPK-signaling pathway and chromatin-remodeling gene mutations. These well-characterized melanoma PDXs and cell lines can be used not only
as reagents for a large array of biological studies

but also as pre-clinical models to facilitate drug
development.
INTRODUCTION
Although cancer incidence overall declined in the United States
from 2002 to 2011, the incidence rates of melanoma continue to
rise (Ryerson et al., 2016). If diagnosed early, surgical resection
is curative in most melanoma patients. However, roughly 20% of
patients will develop metastatic disease. Melanoma accounts for
approximately 50,000 deaths per year worldwide, over 75% of
skin cancer-related mortality (Corrie et al., 2014). With the cost
of massively parallel sequencing technologies decreasing at a
rapid rate, precision medicine is routinely practiced, in which
the genetic profile of a patient’s melanoma is obtained and
used to guide diagnosis and treatment. This practice is particularly valuable for melanoma due to the malignancy’s severity and
the availability of effective targeted therapies for common mutations (Robert et al., 2015).
Melanoma is characterized by constitutive activation of
the mitogen-activated protein kinase (MAPK)- and/or
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phosphoinositide 3-kinase (PI3K)-signaling pathways and
disruption of the cell cycle. Approximately 45% of melanomas
harbor an activating mutation affecting codon 600 of the
serine/threonine-protein kinase BRAF (BRAF V600E), against
which targeted inhibitors (BRAFis) were developed (Davies
et al., 2002; Chapman et al., 2011; Krepler et al., 2016).
BRAFis provide clinical benefit to a large percentage of
advanced melanoma patients whose tumors harbor a BRAF
V600E mutation. However, median progression-free survival
is approximately 6 months (Chapman et al., 2011; Hauschild
et al., 2012). Combining BRAFi with MEK inhibitor (MEKi)
therapy increases responses rates and approximately doubles
median progression-free survival (Robert et al., 2015). Nevertheless, drug resistance is still a major hurdle in the long-term
management of melanoma with targeted therapies (Wagle
et al., 2014). Simultaneously, immune checkpoint inhibitors
have been increasingly used for melanoma treatment. These
agents (anti-CTLA-4, anti-PD-1, and anti-CTLA-4/anti-PD1)
have demonstrated increasing rates of responses in clinical
trials, many of which are durable (i.e., >2 years) (Larkin
et al., 2015). Targeted and immunotherapy combinations are
currently being explored.
In recent years, several large-scale massively parallel
sequencing studies have provided valuable insights into the genetics of melanoma. Initial whole-exome sequencing studies
demonstrated that NF1, ARID2, PPP6C, RAC1, SNX31,
TACC1, and STK19 are significantly mutated genes in melanoma
(Hodis et al., 2012; Krauthammer et al., 2012). The Cancer
Genome Atlas Skin Cutaneous Melanoma (SKCM-TCGA) exome
sequencing dataset identified several additional significantly
mutated melanoma genes, namely, MAP2K1, IDH1, RB1, and
DDX3X (Cancer Genome Atlas Network, 2015). The same groups
classified melanomas into genetic subtypes as follows: BRAF
mutant, RAS mutant, NF1 mutant, and the triple wild-type
(WT/WT/WT). Rare, low-frequency, driver mutations were identified in the WT/WT/WT subtype in KIT, CTNNB1, GNA11, and
GNAQ. Additionally, an apparent increase in copy number variation (CNV) frequency in WT/WT/WT, particularly copy number
amplifications, was detected in driver genes. Further, wholeexome sequencing studies revealed that NF1 mutant melanomas frequently carry additional mutations in other MAPKsignaling pathway genes (Krauthammer et al., 2015; Arafeh
et al., 2015).
As sequencing of patient tumors continues to reveal the widespread genetic variability of melanomas, there is a critical need
for genetically annotated melanoma translational models that
accurately recapitulate the biology and molecular characteristics
of the patient’s original tumor for use in pre-clinical studies to
develop personalized treatment strategies. We sequenced
genes previously implicated in melanomagenesis to evaluate
mutations and copy number changes in 115 human melanoma
cell lines, 248 patient-derived xenografts (PDXs), 31 cell lines
derived from PDXs (PDX CLs), and 68 patient tumors (462 samples total). Of the patients with melanoma, 263 were treatment
naive and 54 were previously exposed to immunotherapy with
anti-CTLA-4 or anti-PD-1, 34 to targeted therapy with BRAFi
and/or MEKi, and 20 to a combination of targeted and
immunotherapy.

RESULTS
Demographic and Clinicopathological Characteristics
of Sequenced Cell Lines, PDXs, Patient Tumors, and
PDX CLs
Sequencing was performed on cell lines, PDXs, and patient tumors. Of 115 Wistar Melanoma cell lines generated at the Wistar
Institute, partial characterization has been reported on a subset
(Hoek et al., 2006; Lin et al., 2008), and 31 additional lines were
developed from PDX models. A further 314 tumor samples representing 253 individuals were either made into PDXs or directly
sequenced from patients treated at the University of Pennsylvania (UPENN, 112), MD Anderson Cancer Center (MDACC, 86),
Massachusetts General Hospital (23), Helen F. Graham Cancer
Center (17), Jefferson (2), John Wayne Cancer Institute (8), Wills
Eye Institute (4), and University of Duisburg-Essen (1). Three patients (1%) had stage II melanoma, 34 (7%) patients had stage III,
106 (42%) patients had stage IV, and for 115 (45%) the patient’s
stage at biopsy was unknown. Clinicopathological characteristics are summarized in Table S1; further details can be found in
the companion paper (Krepler et al., 2017). Twenty-two samples
(6% of unique cohort) were non-cutaneous melanomas, with
mucosal (10, 3%), acral cutaneous (7, 2%), and uveal (5, 1%) primaries included.
Variability among Cell Lines, PDXs, PDX CLs, and
Patient Tumors
Tumors were sequenced on a custom capture panel of 108
genes (MEL V1) known to be important in melanomagenesis
(Table S2). The full genes (exons and introns) were sequenced
for tumor suppressors to facilitate copy number calling, with a
few exceptions. Exons only were sequenced for oncogenes.
We developed an in-house annotation pipeline to classify
variants as deleterious, likely deleterious, and of unknown
significance (see the Experimental Procedures and Figure S1).
Variants and copy number alterations (CNAs) were identified in
all 108 targeted genes. A subset (101) was sequenced on a
119-gene panel (MEL V2) (Table S3); 106 genes were shared
with MEL V2. Of 101 samples (36 unique patients), 45 were
sequenced on both panels, enriched for non-BRAF V600E/K/D
and non-NRAS Q61 mutant samples. The deleterious/likely deleterious variant concordance rates of MEL V1 and MEL V2 were
94% (217 of 231 MEL V1 variants found on MEL V2) and 97%
(217 of 223 MEL V2 variants found on MEL V1) (Figure S2).
Testing results for mutations in the major driver melanoma genes
(BRAF, RAS, NF1, and KIT) did not differ.
Following variant calling, all 115 cell lines harbored at least one
deleterious mutation, compared to 236 of 248 PDXs (95%), 30 of
31 PDX CL (97%) samples, and 59 of 68 patient tumors (87%).
Likely deleterious mutations were found in 69 of 115 cell lines
(60%), 168 of 248 PDXs (67%), 18 of 31 PDX CLs (58%), and
36 of 68 patient tumors (53%). Variants of unknown significance
(VUSs) were found in 103 of 114 cell lines (90%), 222 of 248 PDXs
(93%), 27 of 31 PDX CLs (87%), and 55 of 68 patient tumors
(81%). Table S5 lists all called variants in our cohort. Among all
four sample types, the total number of calls (deleterious/likely
deleterious/VUS) did not differ significantly (Figure 1B). However,
the alternate allele fractions (AAFs) of variants detected across
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Figure 1. Variability among Four Different Sample Types (PDX CL, PDX, Patient Tumor, and Cell Line)
(A) Average number of deleterious variants detected per sample.
(B) Average number of total filtered variants detected per sample.
(C) Allelic fractions across the four sample types.
(D) Major subtypes (BRAF hotspot, RAS hotspot, NF1 hotspot, and WT/WT/WT) and their differential distribution among the entire cohort.
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all sample types were statistically significant different (p = 2.2 3
1016). Patient tumors had the lowest AAF, presumably due to
admixture with non-tumor cells, and PDX CLs had the highest
AAF (Figure 1C).
We compared the prevalence of common mutations across
the four sample types. In the samples from the 371 unique individuals, 203 (55%) had mutations in BRAF, 72 (19%) in RAS
(NRAS and KRAS), and 22 (6%) in NF1 (Figure 1D). As discussed
in detail below, some samples had mutations in more than one of
these genes, and for this purpose they were included in the most
prevalent mutation group (e.g., those with BRAF and RAS mutations in the BRAF mutant group and those with RAS and NF1 mutations in the RAS group). Seventy-four samples (20%) did not
have mutations in the above genes (WT/WT/WT); 14 WT/WT/
WT were non-cutaneous melanomas (acral [1, 1%], mucosal
[9, 12%], or uveal [4, 6%]). For nine WT/WT/WT tumor biopsies,
the sample provided may have been normal tissue, as we only
identified one to three VUSs at 50% allele frequency in each;
four did not grow in mice and five have not been tested for
growth. Cell lines had a higher prevalence of both deleterious
BRAF and RAS mutations than PDXs and patient tumors (p =
0.05; Figure 1D). CDKN2A mutations and homozygous deletions
occurred at a higher frequency (74, 68%) in cell lines, compared
to 104 (52%) PDXs and 14 (24%) tumors (p = 3.3 3 107). TP53
mutations and homozygous deletions also occurred at a higher
frequency in cell lines (34%), as compared to PDXs (23%) and tumors (21%), but not significantly. The distribution of mutations in
PDXs and tumors was reflective of what has been reported previously (Cancer Genome Atlas Network, 2015). In contrast, cell
lines were significantly more likely to be BRAF or RAS mutant
with loss of CDKN2A, likely reflecting difficulties establishing
cell lines from NF1 mutant or WT tumors.
Prevalence of Gene Mutations and Predicted Copy
Number Changes
Among all sequenced samples (462), we identified deleterious/
likely deleterious mutations in 101 of 108 genes. To summarize
the prevalence of gene mutations, the percentage of unique patients (371) was calculated. Deleterious mutations were most
prevalent in our cohort in the following genes: TERT promoter
region (215, 62.5% of all samples), BRAF (200, 58.1%), NRAS
(81, 23.51%), TP53 (63, 18.3%), CDKN2A (49, 14.2%), NF1
(35, 10.2%), ARID2 (28, 8.1%), and PTEN (20, 5.8%) (Figure S3A).
Likely deleterious mutations were most frequently detected
in the following: DCC (32, 19% of all samples), GRM3 (30,
17.9%), PTPRP (19, 11.3%), PREX2 (19, 11.3%), GRIN2A (19,
10%), and PTEN (17, 10.1%) (Figure S3B). Variants were not detected in CD274, MDM4, SDHD, or SMARCB1.
Of the 371 unique samples, 294 unique samples (79%) had a
homozygous loss or high amplification in at least one gene.
The mean (and range) of the number of highly amplified (copy
number > 3.3) and homozygously deleted genes per sample
was 1 (0 to 5) and 2 (0 to 8), respectively. The most frequently
highly amplified genes were the following: CDK6 (91, 30%),
MET (79, 26.1%), DDX3X (69, 22.8%), BRAF (68, 22.4%),
DYNC1I1 (55, 18.2%), EZH2 (51, 16.8%), MITF (49, 16.2%),
MYC (45, 14.9%), PREX2 (45, 14.9%), STK19 (43, 14.2%), and
NOTCH2 (30, 10%) (Figure S3C). The genes most frequently

homozygously deleted were the following: CDKN2A (130,
65.3%), CDKN2B (102, 51.3%), PTEN (47, 23.6%), and TP53
(12, 6%) (Figure S3D). A complete list of CNAs can be found in
Table S6.
MAPK-Signaling Pathway Mutations
The mutational landscape of our samples revealed two distinct
patterns of mutations within the MAPK-signaling pathway: (1)
single-hotspot BRAF or NRAS mutations; and (2) multiple nonhotspot variants across different genes encoding proteins within
the MAPK-signaling pathway, including NF1 mutations. Across
our naive and immunotherapy cohort (317 patients, 85% of
unique cohort), 206 melanomas representing unique individuals
(65% of naive and immunotherapy cohort) followed pattern 1;
148 had solitary driver mutations in BRAF (72%) and 58 (28%)
in NRAS. Pattern 2 melanomas representing 52 unique individuals (14% of unique; 16% of naive and immunotherapy cohort)
had more than one deleterious or likely deleterious mutation in
either an MAPK-signaling gene or in a gene encoding an effector
protein of the MAPK pathway, as shown in Table 1. Three pattern
2 samples were acral (2) and mucosal (1). Eighteen samples
harbored a deleterious or likely deleterious non-V600 BRAF
mutation (p.H57Y, p.G464E, p.S465Y, p.G466E, p.G469E,
p.L496V, p.N581S, p.N581Y, p.D594G, p.V624F, p. K601E,
and p.600_601del) (Figure S4). We also noted an additional
six non-V600 BRAF mutations, which we designated as VUSs
but that may have functional significance (p.G7S, p.F294L,
p.S365L, p.S365L, p.A497V, and p.T740A). We also identified
five BRAF non-V600 variants (p.G9A, p.L505H, p.P318S,
p.P328S, and p.A366P) in samples also carrying V600E mutations, which are less likely to be functional. All non-V600 BRAF
mutations had concurrent deleterious/likely deleterious mutations or high-level amplifications in other MAPK-signaling genes.
Co-occurring RAS deleterious mutations were most frequent,
found in 60% of non-hotspot BRAF mutant samples as
compared to 2%, 6.3%, and 21.5% of those with BRAF
V600E, V600K, and other BRAF hotspot mutations, respectively
(p < 0.0001). Most melanomas had a single second deleterious
mutation in a MAPK-signaling gene; a few had three. We identified concurrent mutations or amplifications in other MAPKsignaling pathway genes in all BRAF non-V600 codon mutations,
except for one, which had incomplete sequencing.
Twenty-three RAS mutants had co-occurring mutations in the
MAPK-signaling pathway (Table 1; Figure S4), and, therefore,
they fell into pattern 2, compared to 58 pattern 1 RAS mutant
samples (53, 91% Q61; 5, 9% non-Q61). Eleven Q61 (17%
of all Q61) and 13 non-Q61 (75% of all non-Q61) mutated melanoma samples harbored additional mutations in the MAPKsignaling pathway (p = 2.2 3 1016 for enrichment of non-Q61
mutations). Of the 30 NF1-mutated melanomas, 26 (87%)
harbored concurrent deleterious/likely deleterious MAPKsignaling pathway mutations (Table 1). Two of the remaining
four NF1-mutated melanomas had VUSs in MAP3K5 (WM4242
also had a deleterious mutation in ROS1 [c.780-1G > A]). Of
the four possible mutations observed in RASA2 (one truncating
and three likely deleterious missense), only two were observed
in NF1 mutant samples. Four of nine (44%) KIT mutant
samples also carried concurrent MAPK pathway mutations.
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Table 1. Samples with Co-occurring Mutations in the MAPK-Signaling Pathway

Green, high-level amplification (>3.3 fold); red, deleterious mutations; blue, likely deleterious mutations; gray, samples and genes not sequenced on
the 119-gene panel; purple, loss of wild-type allele; peach, non-cutaneous melanoma.

Four wild-type (WT/WT/WT) samples in this cohort harbored
likely deleterious and deleterious mutations in MAP2K1/2 and
MAP3K5, including one with a truncating deleterious mutation
in MAP3K5 (p.E477X) (Figure S5).
Genetic/Genomic Landscape of Sequenced Naive
Melanoma Cell Lines, PDXs, PDX CLs, and Patient
Tumors
Deleterious mutations, homozygous losses, and high-level copy
number amplifications in the 225 naive-to-treatment samples
are shown in Figure 2; only one sample from each patient is
included. Likely deleterious mutations and other genomic aberrations also are included in Figure S6. As deleterious TERT
promoter mutations (Table S4) were detected in 67% of samples, and ubiquitously in all subtypes, they are not included in
Figures 2 and S6A.
Within BRAF-V600E mutant treatment-naive samples, we
observed previously well-described subtypes. Of 105, 44
(42%) BRAF V600E-mutated samples from unique patients
harbored truncating and/or deleterious missense mutations in
cell cycle genes (CDKN2A, CDK4, and/or TP53). The remaining
61 (58%) BRAF V600E-mutated samples had more frequent
homozygous loss of CDKN2A/B (46% versus 25%; p = 0.03),
but not PTEN (25% versus 11%). Homozygous deletions in
PTEN occurred almost exclusively in BRAF V600E samples
(91%) (p < 0.0001). Within the subset of BRAF V600E-mutated
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samples lacking additional CDKN2A, CDK4, and/or TP53 mutations, 10 samples (9.5% of unique patients) lacked the C > T
nucleotide substitution pattern characteristic of UV sun damage (Brash, 2015), possibly due to low mutation burden. NF1
mutant samples had the highest overall mutational burden of
all subtypes (p = 1 3 106), the majority of which were C > T
transitions. Of 11 NF1 mutant samples from unique patients,
seven samples (64%) harbored a deleterious mutation in
TP53, more frequently than in other subtypes (p = 0.003). Ten
of 29 WT/WT/WT (34.5%) harbored previously reported rare
mutations in GNAQ, GNA11, and CTNNB1, in a mutually exclusive fashion, six of which were uveal PDX and cell lines. A
further two WT/WT/WT samples (7%) were acral and mucosal
melanomas.
Multiple samples displayed high-level copy number amplifications. Of 27, 19 (70%) high amplifications in MITF occurred
in BRAF V600E-mutated samples. Of the 12 co-occurrences
of high amplification in FGF3/4 and/or CCND1, nine (75%)
also harbored high amplification in MITF. FGF3, FGF4, and
CCND1 are co-localized at 11q13.3, explaining co-occurrence, whereas MITF is on chromosome 3, suggesting a
synergistic effect. Of 31, 25 (80.6%) concurrent amplifications in BRAF, MET, and/or EZH2 occurred in BRAF hotspot
mutant samples (p = 0.009). Three very high-level BRAF
amplification events (6- to 16-fold) were identified, two of
which were in BRAF V600K mutants. Finally, 14 of 24 (58%)

Figure 2. Mutational and Copy Number Profile of Naive Melanoma Cell Lines, PDXs, PDX CLs, and Tumors
A single sample from each of 225 unique patients is included. NMVD, no missense variants in targeted genes detected.

high-amplification events in NOTCH2 co-occurred with high
amplification in NRAS; both are on 1p. Of note, WT/WT/WT
patients harbored significantly lower numbers of CNAs
compared to hotspot BRAF and RAS subtypes (p < 1 3
104), but not to NF1-mutated samples.
We performed formal correlation analyses to examine cooccurrence of copy number changes that were found in more
than 10% of samples (Figures S6B and S6C). When all samples
were considered, significant correlations were identified
between co-localized genes, such as deletion of CDKN2A/
CDKN2B (9p21.3) and amplifications of PREX2/SNX31/MYC
(8q) and BRAF/RAC1/EGFR/EZH2/GRM3/DYNC1I1/CDK6/MET
(chr 7). Significant correlations between non-co-localized genes
also were observed, with the most significant being between
MITF amplification and CDKN2A deletion (p = 0.0005), MITF and
EGFR amplifications (p = 0.0005), and STK19 and AKT3 amplifications (p = 2 3 105) (Figure S6B). The first two correlations are
due to co-enrichment in BRAF-mutated samples. Within the
BRAF mutant subset, the only correlation that emerged was
between MYC and STK19 amplifications (p = 0.0001) (Figure S6C). Little is known about STK19 in melanoma; these data
suggest further functional evaluation is warranted.

Genetic Landscape of Melanoma Cell Lines, PDXs, PDX
CLs, and Patient Tumors Exposed to Targeted Therapies
Forty-nine (54 samples) unique patients had samples taken
either post-progression (37) or on treatment (12) with targeted
therapy; 21 (43%) were treated with a combination of BRAFi
and MEKi, 27 (55%) BRAFi alone, and one MEKi alone (Figure 3A). Post-progression PDXs were expanded in vivo on a
continuous BRAFi or BRAFi/MEKi to maintain the resistance
phenotype (Krepler et al., 2016). Twenty (41%) patients received
a combination of targeted and immunotherapy.
Potential resistance mechanisms were identified for 29 of 36
(81%) patients that progressed on treatment (Figure 3B) and
classified into four categories: BRAF high-level amplifications
(10, 28%), NRAS mutant (6, 17%), MAP2K1 mutant (p.C121S,
p.K57E/N, p.P124S, and p.Q56P) (7, 19%), and non-MAPK
pathway alterations (MITF and MET high amplification and
PTEN homozygous loss) (5, 14%). Although no deleterious mutations in MAP2K2 were identified, a VUS (p.K61E) was found in
the non-MAPK pathway-altered group, which may be associated with resistance. MAP2K2 p.K61E has been reported in a
patient with cardio-facio-cutaneous syndrome, one of the
Rasopathies, supporting a functional role (Dentici et al., 2009).
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Figure 3. Mutational and Copy Number Profile of PDXs, PDX CLs, and Tumors from Patients that Received Targeted Therapy with BRAFi,
MEKi, or a Combination
(A) A single sample from each of 49 unique patients is included.
(B) Five subtypes of potential resistance mechanisms in samples that progressed post-treatment.
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Additional genetic and genomic changes were observed that
also may contribute to therapeutic resistance (Figure 3B). Homozygous loss of PTEN and high-level amplification of MET were
seen in 20% and 50% of patients with high-level amplification
of BRAF, respectively. High-level amplification of BRAF was
observed in 67% of samples also having secondary NRAS
Q61/G12 mutations, along with additional CNAs in non-MAPK
pathway genes. The mechanisms of resistance found in the samples did not differ between patients treated with BRAFi alone and
with BRAFi/MEKi.
Genetic Landscape of Melanoma Cell Lines, PDXs, PDX
CLs, and Patient Tumors from Patients Treated with
Immunotherapy
Overall, 71 unique patients (two acral) were previously exposed
to immunotherapy with anti-CTLA4 (33, 46%), anti-PD-1 (19,
27%), or anti-CTLA4/anti-PD1 (19, 27%). Twenty patients
(28%) received both immunotherapy and targeted therapy. Of
the 71 patients, eight (11%) patients were responders (one
acral), 33 (47%) had progressive disease, seven (10%) had stable disease, and one patient (1%) had a mixed response (Figure 4). Disease outcome was unknown for 22 (31%) patients
(one acral). The genetic and genomic landscape was similar
to the naive sample set, with an enrichment for non-BRAFmutated tumors. However, mutational burden (nonsynonymous
variants/mb) in patients that received immunotherapy was significantly higher than the naive cohort (p = 0.03).
Evaluation of Multiple Samples from the Same Patient
Multiple samples from 40 patients were sequenced, including
cell lines, PDXs, PDX CLs, and biopsies (Figure S7; Table S7).
Full mutational concordance was observed across 65 samples
from 28 (70%) patients; 35 samples from 12 patients were
discordant. In six instances, discordance could be attributed to
within-patient tumor heterogeneity, three instances to within-tumor heterogeneity, one instance to the development of acquired
resistance mutations, two to acquired resistance mutations in
cell lines adapting to targeted therapy, and in two instances no
potential etiology could be identified. Discordant deleterious mutations in KRAS (p.A146T and p.K117N), PTEN, and TACC1 were
found in two biopsies taken on the same day but from different
locations in a patient progressing on pembrolizumab/dabrafenib
(WM4420). One patient had a total of five biopsies at three
different time points; discordant mutations were observed in
three genes, varying over time (before and after treatment with
ipilimumab) and location (WM4295). We also observed discordant mutations in five genes in biopsies taken from left and right
axillary lymph node metastases (WM4413). Further, an early-intransit metastasis was found to have a deleterious TP53 mutation, with two subsequent biopsies from different locations, while
the patient was on BRAFi therapy for 12 months, both TP53 WT
(WM4011). Interestingly, the thick primary melanoma differed
remarkably from a residual lung metastasis after anti-CTLA4
therapy (WM4210). We also observed two instances in which
tumor grafts from the same PDX expanded in different mice
did not have the same mutational changes.
These data suggest that intra-tumoral heterogeneity can lead
to the outgrowth of several sub-clones during the propagation of

PDX, and they may explain some of the heterogeneity seen in
PDX efficacy studies (Krepler et al., 2016). Therapeutic pressures
also can lead to new mutations conferring selective growth
advantages. In the BRAF V600E mutant model WM4351, two
PDXs derived from therapy-naive biopsies were both NRAS
WT, whereas a biopsy taken after progression on BRAFi/MEKi
had an NRAS Q61K mutation. In two cases, PDXs derived
from targeted therapy-progressed patients did not demonstrate
any acquired mutations, but they were resistant to the same therapy the patient had received when dosed in vivo. When we established cell line cultures, they initially did not grow, but they
became resistant after several passages. Each cell line had
a resistance mutation, one in NRAS (Q61K allele frequency
0.44) and the other in MAP2K1 (C121S allele frequency 0.43)
(Table S7).
Chromatin-Remodeling Gene Mutations in Melanoma
Cell Lines, PDXs, PDX CLs, and Patient Tumors
Mutations in the genes that encode the SWI/SNF chromatinremodeling enzymes ARID1A (BAF250A/SMARCF1), ARID1B
(BAF250B), ARID2 (BAF200), and SMARCA4 (BRG1) have
been implicated in melanoma, as have those that encode other
chromatin organization/histone modification proteins (EZH1,
EZH2, SETD2, and TRRAP) (Hodis et al., 2012; Cancer Genome
Atlas Network, 2015). Overall, 65 of 371 (17.5%) samples from
unique patients harbored a likely deleterious/deleterious mutation in at least one of the genes associated with chromatin
remodeling or chromatin organization/histone modification (Figure 5). The most frequently mutated were ARID2 (23), followed by
ARID1A (13), ARID1B (7), and SMARCA4 (4). Deleterious mutations in ARID2, ARID1A, and SMARC4 were mutually exclusive
(p = 2.2 3 1016), apart from a co-occurrence of ARID2 and
SMARCA4 in one sample. However, deleterious mutations in
ARID1B were found concurrently with mutations in ARID2 (1)
and ARID1A (2). Restricting to naive samples to reduce bias,
BRAF V600E mutations were the least likely to be associated
with chromatin-remodeling gene mutations (7 of 105, 7%). Chromatin-remodeling gene mutations were observed comparatively
frequently with BRAF V600K (3 of 15, 20%), RAS (12 of 50, 24%),
and NF1 (1 of 11, 9%) mutations (p = 0.013). One deleterious
truncating mutation was detected in EZH1; deleterious/likely
deleterious missense mutations were found in 12 EZH1/2mutated samples from unique patients. Rare mutually exclusive
mutations were found in SETD2 (4), TRRAP (4), IDH1 (1), and
BAP1 (1).
Comparison of Genotypes in Clinical Samples and PDXs
Clinical tumor sequencing data from 79 melanoma patients
treated at Penn Medicine or MDACC were compared to our
data (Table 2). At the Center for Personalized Diagnostics at
Penn Medicine, the TruSeq Amplicon Cancer Panel (Illumina)
was used for clinical sequencing (Hiemenz et al., 2016). At
MDACC, CMS50 (Life Technologies) was used for clinical
sequencing (Kim et al., 2017). For each patient, mutational profiles of PDX or tumor biopsy were compared to the clinical
mutational profile. It is important to note that, in virtually all
cases, a different sample was used for clinical sequencing
than to establish the PDX or sent as a research tumor biopsy.
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Figure 4. Mutational and Copy Number Profile of PDXs, PDX CLs, and Tumors from Patients that Received Immunotherapy with AntiCTLA-4, Anti PD-1, or a Combination
A single sample from each of 49 unique patients is included. NMVD, no missense variants in targeted genes detected.

Additionally, we could only compare samples for which positive
results were found on either clinical or study sequencing in regions covered by both. All deleterious mutations were determined to be such by both the site and study. However, for
six likely deleterious mutations and VUSs, the pathogenicity
calls varied.
Overall, there were 101 potentially overlapping mutations, of
which 91 (91%) were found by both the site and study. We iden-
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tified eight of 63 (12.6%) samples with discordant results.
Of those, four (WM3407, WM4428, WM4462, and WM4464)
research biopsies were likely normal tissue rather than melanoma, as they had one to three VUSs at allelic frequencies
of 50%. For two samples (WM4433 and WM4323), although
clinical sequencing was done on a pre-treatment sample, we
sequenced a post-treatment sample and identified presumably
de novo resistance mutations. In one sample (WM4279), we

Figure 5. Mutational and Copy Number Profile in Unique Patient Cell Lines and PDXs with a Likely Deleterious/Deleterious Mutation in
Chromatin-Remodeling Genes, which Reveals Mutual Exclusivity of Mutations

identified a KIT p.L576P mutation not found in the clinical samples. Of the 16 UPENN samples with sequencing of a clinical
sample and PDX, we only found one (6%) with discrepant results; interestingly, we each found different truncating mutations
in PTEN. We observed that mutations tended to have higher

allele frequencies in the PDX, as compared to clinical
sequencing, which could be due to either admixture in the original tumor or loss of the wild-type allele during establishment of
the PDX, which we have observed for ovarian cancer PDX
(George et al., 2017).
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Table 2. Results from Clinical and Study Sequencing of Samples from the Same Patient
Sample ID

Sample Type

Clinical
Site

Gene

NT Change

Site Variant
Call

Study
Variant Call

WM4428

patient biopsy

MDACC

BRAF

c.T1799A:p.V600E

deleterious

–

Percentage
Tumor

Tumor
AF (%)

PDX
AF (%)
–

Percentage
Increase

Concordance
discordant

WM4433

patient biopsy

MDACC

BRAF

c.T1799A:p.V600E

deleterious

deleterious

22.6

concordant

WM4433

patient biopsy

MDACC

NRAS

c.A182G:p.Q61R

–

deleterious

32.5

discordant

WM4435

patient biopsy

MDACC

BRAF

c.T1799A:p.V600E

deleterious

deleterious

28.4

concordant

WM4437

patient biopsy

MDACC

BRAF

c.GT1798_1799AA:p.V600K

deleterious

deleterious

33.7

concordant

WM4444

patient biopsy

MDACC

BRAF

c.GT1798_1799AA:p.V600K

deleterious

deleterious

90

concordant

WM4449

patient biopsy

MDACC

BRAF

c.T1799A:p.V600E

deleterious

deleterious

56.9

concordant

WM4462

patient biopsy

MDACC

BRAF

c.T1799A:p.V600E

deleterious

–

–

discordant

WM4464

patient biopsy

MDACC

BRAF

c.T1790G:p.L597R

deleterious

–

–

discordant

WM4472

patient biopsy

MDACC

BRAF

c.T1799A:p.V600E

deleterious

deleterious

44.3

concordant

WM4478

patient biopsy

MDACC

BRAF

c.A1801G:p.K601E

deleterious

deleterious

42.4

concordant

WM4487

patient biopsy

MDACC

BRAF

c.T1799A:p.V600E

deleterious

deleterious

52.1

concordant

WM4494

patient biopsy

MDACC

BRAF

c.GT1798_1799AA:p.V600K

deleterious

deleterious

29.2

concordant
concordant

WM4500

patient biopsy

MDACC

BRAF

c.T1799A:p.V600E

deleterious

deleterious

53.8

WM4508

patient biopsy

MDACC

BRAF

c.1799_1801del:p.600_601del

deleterious

deleterious

36.4

concordant

WM4515

patient biopsy

MDACC

NRAS

c.A182G:p.Q61R

deleterious

deleterious

50.8

concordant

WM4528

patient biopsy

MDACC

NRAS

c.C181A:p.Q61K

deleterious

deleterious

41.8

concordant

WM4530

patient biopsy

MDACC

NRAS

c.A182G:p.Q61R

deleterious

deleterious

48

concordant

WM4532

patient biopsy

MDACC

BRAF

c.T1799A:p.V600E

deleterious

deleterious

47.5

concordant

WM4542

patient biopsy

MDACC

NRAS

c.A182G:p.Q61R

deleterious

deleterious

46.2

concordant

WM4545

patient biopsy

MDACC

BRAF

c.T1799A:p.V600E

deleterious

deleterious

44.6

concordant

WM4553

patient biopsy

MDACC

BRAF

c.T1799A:p.V600E

deleterious

deleterious

49.4

concordant

WM4558

patient biopsy

MDACC

BRAF

c.T1799A:p.V600E

deleterious

deleterious

47.7

concordant

WM3407

PDX

MDACC

BRAF

c.G1397A:G466E

deleterious

ND

–

discordant

WM3407

PDX

MDACC

ATM

c.T728C:p.L243S

VUSz

VUS

48.1

concordant

WM4218

PDX

MDACC

KIT

c.T1669C:p.W557R

deleterious

deleterious

47.1

concordant

WM4249

PDX

MDACC

BRAF

c.T1799A:p.V600E

deleterious

deleterious

61.7

concordant

WM4257

PDX

MDACC

NRAS

c.C181A:p.Q61K

deleterious

deleterious

75

concordant

WM4257

PDX

MDACC

TP53

c.G629A:p.R210K

deleterious

deleterious

100

concordant

WM4258

PDX

MDACC

BRAF

c.T1799A:p.V600E

deleterious

deleterious

48.1

concordant

WM4260

PDX

MDACC

KIT

c.A1924G:p.K642E

deleterious

deleterious

78.3

concordant

WM4260

PDX

MDACC

CTNNB1

c.C134T:p.S45F

deleterious

deleterious

49.9

concordant

WM4262

PDX

MDACC

BRAF

c.T1799A:p.V600E

deleterious

deleterious

99.8

concordant

WM4264

PDX

MDACC

BRAF

c.T1799A:p.V600E

deleterious

deleterious

64.7

concordant

WM4265-1

PDX

MDACC

NRAS

c.C181A:p.Q61K

deleterious

deleterious

96.8

concordant

WM4265-1

PDX

MDACC

TP53

c.C380T:p.S127F

deleterious

deleterious

98

concordant
(Continued on next page)

Table 2.

Continued

Sample ID

Sample Type

Clinical
Site

Gene

NT Change

Site Variant
Call

Study
Variant Call

Percentage
Tumor

Tumor
AF (%)

PDX
AF (%)

Percentage
Increase

WM4267

PDX

MDACC

BRAF

c.T1799A:p.V600E

deleterious

ND

–

discordant

WM4267

PDX

MDACC

CDKN2A

c.G159C:p.M53I

VUS

VUS

55.1

concordant

Concordance

WM4276

PDX

MDACC

BRAF

c.T1799A:p.V600E

deleterious

deleterious

0.61

concordant

WM4279

PDX

MDACC

KIT

c.T1727C:p.L576P

ND

deleterious

86.6

discordant

WM4280

PDX

MDACC

BRAF

c.GT1798_1799AA:p.V600K

deleterious

deleterious

47.6

concordant

WM4285

PDX

MDACC

BRAF

c.T1799A:p.V600E

deleterious

deleterious

42.2

concordant

WM4286-1

PDX

MDACC

BRAF

c.T1799A:p.V600E

deleterious

deleterious

0.59

concordant

WM4292

PDX

MDACC

BRAF

c.T1799A:p.V600E

deleterious

deleterious

48.6

concordant

WM4295

PDX

MDACC

NRAS

c.A182T:p.Q61L

deleterious

deleterious

96.3

concordant

WM4299-1

PDX

MDACC

NRAS

c.A182T:p.Q61L

deleterious

deleterious

0.93

concordant

WM4306

PDX

MDACC

BRAF

c.T1799A:p.V600E

deleterious

deleterious

25.2

concordant

WM4323

PDX

MDACC

BRAF

c.T1799A:p.V600E

deleterious

–

–

discordant
discordant

WM4323

PDX

MDACC

MAP2K1

c.1029dupA:p.I343fs

NCy

deleterious

46.2

WM4335

PDX

MDACC

BRAF

c.T1799A:p.V600E

deleterious

deleterious

28.7

concordant

WM4345

PDX

MDACC

BRAF

c.T1799A:p.V600E

deleterious

deleterious

61

concordant

WM4345

PDX

MDACC

CDKN2A

c.C238T:p.R80X

deleterious

deleterious

84

concordant

WM4351

PDX

MDACC

BRAF

c.T1799A:p.V600E

deleterious

deleterious

75.5

concordant

WM4353

PDX

MDACC

BRAF

c.T1799A:p.V600E

deleterious

deleterious

57

concordant

WM4367

PDX

MDACC

BRAF

c.T1799A:p.V600E

deleterious

deleterious

51.2

concordant

WM4369

PDX

MDACC

NRAS

c.G38A:p.G13D

deleterious

deleterious

65.6

concordant
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WM4370

PDX

MDACC

BRAF

c.GT1798_1799AA:p.V600K

deleterious

deleterious

92.7

concordant

WM4380

PDX

MDACC

BRAF

c.T1799A:p.V600E

deleterious

deleterious

30.7

concordant

WM4382

PDX

MDACC

BRAF

c.T1799A:p.V600E

deleterious

deleterious

48.6

concordant

WM4388

PDX

MDACC

BRAF

c.T1799A:p.V600E

deleterious

deleterious

47

concordant

WM4388

PDX

MDACC

TP53

c.C520T:p.R174X

deleterious

deleterious

91.3

concordant

WM4389

PDX

MDACC

NRAS

c.G37C:p.G13R

deleterious

deleterious

73.1

concordant

WM4404

PDX

MDACC

BRAF

c.T1799A:p.V600E

deleterious

deleterious

67.7

concordant

WM4408

PDX

MDACC

BRAF

c.T1799A:p.V600E

deleterious

deleterious

74.1

concordant

WM4420

PDX

MDACC

BRAF

c.GT1798_1799AA:p.V600K

deleterious

deleterious

87.7

concordant

WM4420

PDX

MDACC

CTNNB1

c.C134T:p.S45F

deleterious

deleterious

65

concordant

WM4420

PDX

MDACC

FBXW7

c.C1321T:p.R441W

deleterious

deleterious

52.6

concordant

WM4426

PDX

MDACC

NRAS

c.A182G:p.Q61R

deleterious

deleterious

84.5

concordant

WM4430

PDX

MDACC

NRAS

c.A182G:p.Q61R

deleterious

deleterious

100

concordant

WM4442

PDX

MDACC

NRAS

c.C181A:p.Q61K

deleterious

deleterious

95.7

concordant

WM4445

PDX

MDACC

BRAF

c.T1799A:p.V600E

deleterious

deleterious

56.7

concordant

WM4451

PDX

MDACC

NRAS

c.G35A:p.G12D

deleterious

deleterious

87.4

concordant
(Continued on next page)
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Table 2.
Sample ID

Continued
Sample Type

Clinical
Site

Gene

NT Change

Site Variant
Call

Study
Variant Call

Percentage
Tumor

Tumor
AF (%)

PDX
AF (%)

Percentage
Increase

Concordance

WM4454

PDX

MDACC

TP53

c.T708G:p.C236W

deleterious

deleterious

100

concordant

WM4454

PDX

MDACC

BRAF

c.T1799A:p.V600E

deleterious

deleterious

45.3

concordant

WM4465

PDX

MDACC

BRAF

c.GT1798_1799AA:p.V600K

deleterious

deleterious

WM3901

PDX

UPENN

BRAF

c.T1799A:p.V600E

deleterious

deleterious

29.2

concordant

44

67.05

84.9

26.6

concordant
concordant

WM4011

PDX

UPENN

BRAF

c.GT1798_1799AA:p.V600K

deleterious

deleterious

2650

13.82

76.6

454.3

WM4042

PDX

UPENN

NRAS

c.A182G:p.Q61R

deleterious

deleterious

>50

34.26

98.9

188.7

concordant

WM4068

PDX

UPENN

BRAF

c.G1406A:p.G469E

deleterious

deleterious

>50

35

47

34.2

concordant

WM4068

PDX

UPENN

KRAS

c.G35A:p.G12D

deleterious

deleterious

>50

61.1

73.7

20.6

concordant

WM4206

PDX

UPENN

BRAF

c.GT1798_1799AA:p.V600K

deleterious

deleterious

>50

35.06

65.6

87.1

concordant

WM4208

PDX

UPENN

NRAS

c.A182G:p.Q61R

deleterious

deleterious

>50

19.13

64

234.6

concordant

WM4224

PDX

UPENN

NRAS

c.A182G:p.Q61R

deleterious

deleterious

44

10.14

47.7

370.4

concordant

WM4224

PDX

UPENN

TP53

c.C211T:p.R71C

deleterious

deleterious

44

12.03

57.6

378.8

concordant

WM4224

PDX

UPENN

CTNNB1

c.A121G:p.T41A

deleterious

deleterious

44

28.5

98.8

246.7

concordant

WM4231

PDX

UPENN

RET

c.C2672T:p.S891L

VUS

likely deleterious

>50

25.68

50.2

95.5

concordant

WM4231

PDX

UPENN

NRAS

c.A182G:p.Q61R

deleterious

deleterious

>50

30.25

52.5

73.6

concordant

WM4237

PDX

UPENN

RB1

c.2069_2082del:p.N690fs

deleterious

deleterious

2650

38.41

73.8

92.1

concordant

WM4237

PDX

UPENN

BRAF

c.T1799A:p.V600E

deleterious

deleterious

2650

21.21

76.3

259.7

concordant

WM4237

PDX

UPENN

TP53

c.C722T:p.S241F

deleterious

deleterious

26 50

40.62

99.2

144.2

concordant

WM4240

PDX

UPENN

SMAD4

c.G1399C:p.G467R

VUS

likely deleterious

100

43.33

41.7

–

concordant

WM4243

PDX

UPENN

BRAF

c.T1799A:p.V600E

deleterious

deleterious

>50

41.06

50.1

22.0

concordant

WM4298

PDX

UPENN

KIT

c.T1688A:p.I563K

likely deleterious

VUS

>50

61.05

98

60.5

concordant

WM4298

PDX

UPENN

BRAF

c.T1799A:p.V600E

deleterious

deleterious

>50

50.9

98.8

94.1

concordant

WM4314

PDX

UPENN

FGFR2

c.811_812delinsAA:p.G271K

likely deleterious

likely deleterious

>50

34.96

46.2

–

discordant

WM4349

PDX

UPENN

BRAF

c.T1799A:p.V600E

deleterious

deleterious

2650

24.63

51.8

110.3

concordant

WM4364

PDX

UPENN

BRAF

c.T1799A:p.V600E

deleterious

deleterious

>50

42.91

55.6

29.6

concordant

WM4364

PDX

UPENN

PTEN

c.208_209+1del

deleterious

ND

>50

72.59

ND

–

discordant

WM4364

PDX

UPENN

PTEN

c.727_728del:p.L243fs

ND

deleterious

>50

ND

78.5

–

discordant

WM4543

PDX

UPENN

KDR

c.G4066T:p.V1356F

VUS

VUS

2650

6.84

44

543.3

concordant

WM4543

PDX

UPENN

BRAF

c.T1799A:p.V600E

deleterious

deleterious

2650

6.4

40.4

531.3

concordant

ND, not detected; NC, not captured; VUS, variant of uncertain significance.

DISCUSSION
In this era of precision medicine, pre-clinical drug development
of targeted oncology therapeutics relies heavily on models of
cancer that have been shown to be representative of the genetic
profile of the patient’s tumor. Herein, we demonstrate that targeted massively parallel sequencing of 108/119 genes previously implicated in melanomagenesis, followed by our custom
analysis pipelines for mutational and CNV calling, is a reliable
method for characterizing the genetic and genomic landscape
of melanoma cell lines, tumors, PDXs, and PDX CLs. To account
for the lack of matched normal samples, control samples were
sequenced in each lane for normalization for copy number calling and to identify common variants, which were subtracted
out. We also removed sequences that more closely aligned to
the mouse than human genome to decrease cross-contamination and increase accuracy of mutational and copy number
calling. We used an in-house-developed pipeline to classify mutations or variants as deleterious, likely deleterious, and VUS,
incorporating information from the literature and Catalogue of
Somatic Mutations in Cancer (COSMIC), mutational type, location, and effect, after filtering for a maximum population frequency greater than or equal to 0.1% to account for the lack of
a matched normal.
We found the total number of mutation and variant calls did not
differ significantly among cell lines, PDXs, PDX CLs, and patient
tumors, although, not surprisingly, there was a trend toward
higher mutational rates in PDXs and cell lines. We observed
significantly higher rates of BRAF and RAS mutations and
CDKN2A mutations/loss in cell lines than PDXs and tumor biopsies, consistent with the growth advantage conferred by those
mutations. However, we did find cell lines representing all mutational groups. We also found an extremely high concordance
rate between clinical sequencing results and our targeted
sequencing, with only two samples of 80 (2.5%) demonstrating
truly discrepant results. Taken together, the mutational profiles
observed in the melanoma cell lines, PDXs, and PDX CLs
sequenced in this study are an accurate genetic and genomic
representation of the patient’s original tumor. We also identified
all major previously reported melanoma subtypes, as well as the
full spectrum of mutations and copy number aberrations, at
roughly the same frequencies identified in large-scale original
patient tumor/normal sequencing studies (Berger et al., 2012;
Hodis et al., 2012; Krauthammer et al., 2015; Cancer Genome
Atlas Network, 2015). Thus, we have a unique genetically and genomically annotated biobank of PDXs, PDX CLs, and cell lines,
representative of the full spectrum of melanoma, which can be
used both for functional studies and pre-clinical drug development studies in melanoma.
Our large sample set also enabled us to describe rare subtypes in greater detail. We found two mutually exclusive patterns
of mutations in the MAPK-signaling pathway: (1) single-hotspot
mutations at BRAF V600 or NRAS Q61; and (2) multiple non-hotspot variants across different genes encoding proteins within the
MAPK-signaling pathway, of which NF1 mutations are a subset.
All deleterious/likely deleterious non-600 mutations in BRAF,
87% of the NF1, 75% of the non-Q61 RAS, and 44% of KIT
mutant samples harbored either a secondary mutation or high-

level amplification in at least one gene encoding a MAPKsignaling protein or an effector protein of the MAPK pathway.
These data are consistent with functional studies that have
demonstrated that kinase-dead BRAF (D594 mutants) needs
oncogenic RAS to drive tumor progression (Heidorn et al.,
2010). Our results also suggest that BRAF mutations (e.g., at
G464 and G469) leading to constitutive dimerization (Yao et al.,
2015) also need at least one additional MAPK-signaling mutation
to drive tumor progression, either a single NRAS G12/13 or multiple other mutations. These data suggest that, to accurately
characterize therapeutic response pre-clinically for non-V600
BRAF or non-Q61 NRAS mutations, a second MAPK-signaling
mutation will be needed to be included in the model. Further,
we can make predictions about the functionality of uncharacterized BRAF non-V600 mutations, in that if the alteration is found
without a secondary MAPK-signaling pathway gene mutation
or in the presence of a BRAF V600 gene mutation, it is very unlikely to have any functional significance. Similar to BRAF nonV600 mutations, RAS G12/13 mutations usually are observed
with co-occurring mutations, most commonly in BRAF and
NF1, suggesting they are not sufficient to drive tumorigenesis
in melanoma, in contrast to other tumor types (Hobbs et al.,
2016).
We identified additional MAPK pathway or co-activating gene
mutations in 87% of NF1 mutant tumors. We did not observe any
difference between those with one or two truncating NF1 mutations or with accompanying loss of the wild-type allele. Prior literature has suggested an enrichment for co-occurring mutations
in Rasopathy genes, particularly PTPN11 and RASA2 (Arafeh
et al., 2015; Cirenajwis et al., 2017; Krauthammer et al., 2015).
However, we observed co-occurrence of deleterious mutations
across numerous genes without specific enrichment, including
those that have not been previously implicated as co-mutated
with NF1, although known to be mutated in melanoma,
MAP3K5 and MAP3K9. Functional studies of BRAFwt/RASwt
melanoma cell lines lacking NF1 expression, or expressing
NF1 at extremely low levels, have shown that not all have RAS
activation and that only some were sensitive to MEKi (Krauthammer et al., 2015). This result may be explained by the co-occurrence of other MAPK-signaling gene mutations. Pre-clinical
modeling of response to therapies for NF1-mutated melanoma
also will need to account for co-occurring mutations. The NF1
mutant cohort harboring co-mutations in MAPK3K5/9 is of
particular interest, as they are upstream activators of the Jun
N-terminal kinase (JNK) and p38 MAPK pathways (Rana et al.,
2013). The current study provides the reagents to further functionally characterize this interesting rare subtype of melanoma.
Although previous sequencing studies have identified
ARID1A/B, ARID2, IDH1, SMARCA4A, TRRAP, and EZH2 as
chromatin-remodeling genes frequently mutated in melanoma
(Berger et al., 2012; Hodis et al., 2012; Zhang et al., 2016), their
mutual exclusivity has not been well described. Given this
finding, it is likely that the previously described ARID1B dependence in ARID1A-mutated ovarian cancer cells (Helming et al.,
2014) is recapitulated in melanoma, as well as the EZH2 dependency in tumors with mutations in ARID1A or SMARCA4 that do
not harbor co-mutations in RAS or BRAF (Kim et al., 2015). However, a few ARID1A- and SMARCA4-mutated samples in our
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dataset do have co-mutations in BRAF or RAS, which has been
postulated to abolish EZH2 dependency (Kim et al., 2015),
so further investigation is needed. The biological relevance of
the likely deleterious missense mutations we identified in
ARID1A/B and ARID2, which occur alone and concurrently
with other ARID1A/B and EZH2 mutations, also needs to be evaluated functionally. Pre-clinical studies using these PDX models
may reveal other specific vulnerabilities in melanomas, with
a mutation in SWI/SNF components ARID1A, ARID1B, ARID2,
or SMARCA4A, that will aid in the development of novel
therapeutics.
We profiled 37 PDXs, PDX CLs, and tumor biopsies from patients that progressed on targeted therapy (either BRAFi or
BRAFi/MEKi). Our evaluation for resistance mechanisms was
limited by a lack of matched pre-treatment or normal samples
and RNA to evaluate for splice variants or potential fusions. However, we identified mutations in NRAS, MAP2K1, and BRAF
amplification at rates similar to other series (Johnson et al.,
2015). Amplification of BRAF was enriched in this set (40%), as
compared to the naive group (15%, p = 2 3 104). For the two
PDXs with high-level BRAF amplifications, it likely is the primary
mechanism of resistance. For other samples with BRAF amplification, it is a potential mechanism of resistance, but it cannot not
be definitively proven as we lacked matched pre-treatment samples. For 51% of samples, we did not identify a clear mechanism
of resistance; in half of those, we found amplifications and
drivers outside the MAPK-signaling pathway that may be associated with resistance. We also profiled PDXs, PDX CLs, and
tumor biopsies from 71 patients that had received checkpoint
blockade therapy. The genetic and genomic landscape of these
samples was similar to naive samples, albeit with increased
mutational burden and enrichment for non-BRAF mutations.
These post-treatment PDXs are ideal for further studies to identify potential resistance mechanisms and pre-clinical studies of
potential therapeutics for tumors resistant to either targeted or
checkpoint therapy.
Our study has several limitations, when compared to prior tumor-based analyses. Although the samples are derived from human tumors, they are established in culture or as PDX models in
T cell-deficient (nude) mice, so they are not subject to an intact
immune system, which may lead to differential selective pressures for mutations or copy number aberrations. Additionally,
intra-tumor heterogeneity observed in PDX expansion (Tentler
et al., 2012) can result in potentially inharmonious PDX/PDX CL
and tumor mutational profiles. We observed a high consistency
between clinical testing and our profiling, likely because the
former mainly included major driver genes. However, when we
sequenced multiple samples from the same individual, we found
several instances of both within-patient and within-tumor heterogeneity. Further, several of the tumor biopsies (but neither PDXs
nor cell lines) that we sequenced that fall into the WT/WT/WT
group may be normal tissue, as histopathology was not done
on these research samples. Platform and analytical differences
also may lead to differences among mutational and copy number
rates among studies. As we did not have a matched normal
sequence for subtraction, we used population-based data,
non-matched normal and stringent calling metrics to identify
deleterious and likely deleterious mutations, but these are imper-
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fect controls. We also chose to only report out high-level amplifications and homozygous deletions, to be conservative. Thus,
for some genes, our data appear different than prior studies.
For example, mutations in GRIN2A and TRRAP are reported in
22% and 12%, respectively, of melanomas in a meta-analysis
of somatic mutations across studies (Zhang et al., 2016); but,
since we classified most variants in these genes as VUSs, our reported rates of deleterious/likely deleterious mutations are much
lower at 6% and 5.6%. Additionally, we are limited by the genes
and regions included in our panel at the time of design, and so we
have not interrogated recently identified recurrently mutated
promoter regions, genes associated with resistance to checkpoint blockage, and the Rasopathy genes in all samples. Performing unbiased whole-exome or whole-genome sequencing
on 462 samples was not possible due to cost restrictions.
This unparalleled biobank of melanoma cell lines, PDXs, and
PDX CLs in this study provides a set of reagents for not only
future melanoma drug discovery and development efforts but
also extensive biological studies. We have characterized 146
cell lines (31 derived from PDXs), 248 PDXs, and 68 tumor biopsies, which include both those naive to treatment and resistant
to targeted therapy and checkpoint blockade. We have been
able to identify all major and minor subtypes of melanoma,
thus providing reagents that, in some cases, were previously unavailable for functional and biological studies. Although further
evaluation will need to be done in some instances to characterize
the reagents (e.g., targeted therapy progression samples for
which no mechanism of resistance was identified), the current
genetic and genomic copy number data provide a strong basis
for future studies. These reagents enable thoughtful pre-clinical
trials to be designed to determine the in vivo efficacy of novel
single-agent and combination therapies in genetically defined
melanoma subsets, as demonstrated in the companion paper
(Krepler et al., 2017).
EXPERIMENTAL PROCEDURES
Sample Acquisition
Acquisition of patient samples for the purposes of establishing PDXs and cell
lines was approved by the corresponding institutions’ institutional review
boards, and informed consent was obtained from each participant for use of
his or her sample in genetic studies. Tumors were provided from the following
institutions: Perelman School of Medicine at the University of Pennsylvania,
MD Anderson Cancer Center, Helen F. Graham Cancer Center, Massachusetts General Hospital, the John Wayne Cancer Institute, the Center for Melanoma and Cancer Immunotherapy at Hadassah Hebrew University Medical
Center’s Sharett Institute of Oncology, and the University of Duisburg-Essen.
A full description of PDX development is given in our companion paper (Krepler et al., 2016). As part of this study, 114 human melanoma cell lines, 246
PDXs, 60 PDX CLs, and 68 patient tumors were sequenced (total number of
samples: 462) (Table S1). In addition to melanoma cell lines, PDXs, and PDX
CLs, 36 unmatched anonymous germline blood samples were sequenced
simultaneously, which were used for the normalization for copy number
calling.
Processing of Sequencing Data
Short-read sequences were aligned to the GRCh37 human reference
genome using the Burrows-Wheeler Aligner (BWA) (Li and Durbin, 2009).
Duplicate reads were flagged, as well as reads that mapped equally to
more than one location. Human reads were further disambiguated from
mouse by aligning to the mm10 reference genome using the Python script

(https://github.com/AstraZeneca-NGS/disambiguate), which takes the human_aligned.bam and the mouse_aligned.bam as input. Reads that
aligned more confidently to the mouse genome, as well as ambiguous
reads between the two species, were discarded. To achieve acceptable
data quality assurance, the Broad Institute’s Genome Analysis Toolkit
(GATK) ‘‘Best Practices’’ guidelines were followed. Single-nucleotide variant
(SNV) and small insertion and deletion (indel) variant calling was performed by GATK UnifiedGenotyper (DePristo et al., 2011; McKenna et al.,
2010), VarDict (Lai et al., 2016), and Freebayes (Garrison and Marth, 2012).
Variants with a read depth less than 20 and alternative allele read depth less
than five, as well as all synonymous variants, and/or variants present in the
germline samples, were excluded. However, variants that were called by
more than one variant caller and had a sequencing depth of less than 20
were not excluded. Variants were annotated with a customized version of
ANNOVAR (Wang et al., 2010). Variants were removed if the minor allele frequency was greater than or equal to 0.1% in the population databases 1000
Genomes (Abecasis et al., 2012) and/or Exome Aggregation Consortium
(ExAC) (Lek et al., 2016) or found in normal germline samples sequenced on
our capture. The remaining annotated variants were classified as outlined in
Figure S1. Variant classification was confirmed with cBioPortal for Cancer Genomics, wherever possible (Cerami et al., 2012), and using ClinVar for the Rasopathy genes (https://www.ncbi.nlm.nih.gov/clinvar/). Integrative Genomics
Viewer was used for visual confirmation of the majority of calls (Thorvaldsdóttir
et al., 2013).
CNV Prediction
CNV from sequencing data were profiled using copy number detection by
exome sequencing (CODEX) (Jiang et al., 2015). CODEX normalizes depth
of coverage using a Poisson latent factor model that removes biases due
to GC content, exon capture and amplification efficiency, and latent
systemic artifacts. Six Poisson latent factors were included in the normalization model for this dataset, which corresponds to sample- and targetwise biases and artifacts that cannot be directly measured or quantified.
Segmentation was restricted to exons for all genes. Only homozygous
loss (copy number < 0.7) and high-amplification (copy number > 3.3)
calls are reported. Visual confirmation of CNV calls was done in Nexus
7.5 (BioDiscovery) software.
Biostatistical Analysis
RStudio version 1.0.136 was used to analyze the data. One-way ANOVA was
used to compare the means of variant calls in cell line, PDX, and PDX CL.
Paired t test (along with 95% confidence interval for the difference in means)
was used to compare allelic fractions of all variants, the number of all filtered
variants among all sample types, the mutational burden between patients
that received immunotherapy and naive ones, and mutational burden comparison of naive NF1 mutants, with other naive subtypes. Chi-square test, Fisher’s
exact test, or an unpaired t test was used to make other statistical comparisons, as appropriate. For cluster analysis based on correlations, a gene with
CNV < 1 or > 1 was selected for data analysis if it was shown from more
than 10% of study samples. Spearman correlation coefficients were calculated between each pair of selected genes, and hierarchical clustering by
Euclidian distance and complete linkage using the heatmap.2 function available from the R Foundation for Statistical Computing (http://www.R-project.
org) was further performed to group the genes based on their correlations.
For all analyses, p < 0.05 was considered statistically significant.
DATA AND SOFTWARE AVAILABILITY
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